Health Care · S&P 500

Moderna

A U.S. biotech company developing medicines such as its COVID-19 vaccine using messenger RNA technology. S&P 500 constituent. Sector: Health Care (Biotechnology). Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.

MRNA Updated Jul 11, 2026 1 AI consumers· 1 recurring

Annual return · 2026-07-10'21+143.1%'22-29.3%'23-44.6%'24-58.2%'25-29.1%YTD+131.5%
Money in·
Moderna~$3.2B
Money out·

Financials & Segments

  • Total revenue · ~$3.2B (FY2024)
  • Segments · COVID-19 vaccine (Spikevax) · RSV vaccine · Other & collaboration

Revenue from

No refined links yet.

Pays to

No refined links yet.


← All companiesMarkdown · JSON

For information only, not investment advice. Content on this site is generated by AI from verified, cross-checked sources and may contain errors.

© 2026 Willow Investments, Inc.Company value-chain data · contact@willowinvt.com